Neurodegenerative disorders: Reversing Huntington's disease.

Tse MT.

Nat Rev Drug Discov. 2012 Aug;11(8):600. doi: 10.1038/nrd3804. No abstract available.

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH.

Hum Mol Genet. 2012 Jan 15;21(2):406-20. doi: 10.1093/hmg/ddr475.

Eugenics, Heredity, and Huntington's Disease: A Brief Historical Perspective.

Wexler A.

J Huntingtons Dis. 2012;1(2):139-41. doi: 10.3233/JHD-129007. No abstract available.

A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington's disease.

Van Camp N, Blockx I, Camón L, de Vera N, Verhoye M, Veraart J, Van Hecke W, Martínez E, Soria G, Sijbers J, Planas AM, Van der Linden A.

Neurobiol Aging. 2012 May;33(5):945-59. doi: 10.1016/j.neurobiolaging.2010.07.001.

Does Huntington's disease enhance cephalad spread during neuraxial anesthesia for cesarean section?

Draisci G, Sbaraglia F, Pinto R, Zanfini BA, Frassanito L, Catarci S.

J Clin Anesth. 2012 Sep;24(6):516-7. doi: 10.1016/j.jclinane.2011.09.011. No abstract available.

Identification and characterization of Huntington related pathology: an in vivo DKI imaging study.

Blockx I, Verhoye M, Van Audekerke J, Bergwerf I, Kane JX, Delgado Y Palacios R, Veraart J, Jeurissen B, Raber K, von Hörsten S, Ponsaerts P, Sijbers J, Leergaard TB, Van der Linden A.

Neuroimage. 2012 Nov 1;63(2):653-62. doi: 10.1016/j.neuroimage.2012.06.032.

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Martin B, Chadwick W, Cong WN, Pantaleo N, Daimon CM, Golden EJ, Becker KG, Wood WH 3rd, Carlson OD, Egan JM, Maudsley S.

J Biol Chem. 2012 Sep 14;287(38):31766-82. doi: 10.1074/jbc.M112.387316.

Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Chen JJ, Salat DH, Rosas HD.

Neuroimage. 2012 Jan 16;59(2):1043-51. doi: 10.1016/j.neuroimage.2011.08.112.

Journal of Huntington's Disease.

Leavitt BR, Thompson LM.

J Huntingtons Dis. 2012;1(1):1. doi: 10.3233/JHD-2012-120001. No abstract available.

The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP.

Neurobiol Dis. 2012 Jul;47(1):75-91. doi: 10.1016/j.nbd.2012.03.025.

Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

Prime ME, Brookfield FA, Courtney SM, Gaines S, Marston RW, Ichihara O, Li M, Vaidya D, Williams H, Pedret-Dunn A, Reed L, Schaertl S, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Domingu

ACS Med Chem Lett. 2012 Aug 9;3(9):731-5. doi: 10.1021/ml3001352.

An unusually low prevalence of Huntington's disease in Iceland.

Sveinsson O, Halldórsson S, Olafsson E.

Eur Neurol. 2012;68(1):48-51. doi: 10.1159/000337680.

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease.

Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR.

Neurobiol Dis. 2012 Dec;48(3):282-9. doi: 10.1016/j.nbd.2012.06.026.

Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study.

Fekete R, Davidson A, Jankovic J.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-86-476-4. doi: 10.7916/D8DN43SC.

CCG polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with Huntington's disease in mainland Chinese families.

Zhang BR, Tian J, Yan YP, Yin XZ, Zhao GH, Wu ZY, Gu WH, Xia K, Tang BS.

J Neurol Sci. 2012 Jan 15;312(1-2):92-6. doi: 10.1016/j.jns.2011.08.015.